MAM
ACAD icon

Meeder Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Meeder Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-984
Closed -$21.9K – 931
2026
Q1 		$21.9K Hold
984
– – ﹤0.01% 552
2025
Q4 		$26.3K Buy
+984
New +$23.5K ﹤0.01% 492
2025
Q2 		– Sell
-26,960
Closed -$448K – 850
2025
Q1 		$448K Buy
+26,960
New +$490K 0.03% 184
2021
Q4 		– Sell
-24
Closed – – 1095
2021
Q3 		$0 Hold
24
– – ﹤0.01% 2461
2021
Q2 		$1K Hold
24
– – ﹤0.01% 2295
2021
Q1 		$1K Sell
24
-43
-64% -$1.89K ﹤0.01% 2162
2020
Q4 		$4K Sell
67
-9
-12% -$447 ﹤0.01% 1252
2020
Q3 		$3K Sell
76
-36
-32% -$1.55K ﹤0.01% 1697
2020
Q2 		$5K Sell
112
-3,133
-97% -$150K ﹤0.01% 1500
2020
Q1 		$136K Sell
3,245
-3,066
-49% -$126K 0.01% 648
2019
Q4 		$271K Buy
6,311
+135
+2% +$5.87K 0.02% 520
2019
Q3 		$221K Buy
6,176
+5,889
+2,052% +$179K 0.01% 583
2019
Q2 		$8K Sell
287
-723
-72% -$18.5K ﹤0.01% 1510
2019
Q1 		$27K Sell
1,010
-2,599
-72% -$60.7K ﹤0.01% 998
2018
Q4 		$57K Buy
3,609
+3,336
+1,222% +$64.8K 0.01% 776
2018
Q3 		$6K Buy
+273
New +$4.29K ﹤0.01% 1278
2018
Q2 		– Sell
-124
Closed -$3K – 1544
2018
Q1 		$3K Hold
124
– – ﹤0.01% 1311
2017
Q4 		$4K Buy
+124
New +$3.96K ﹤0.01% 1347

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Meeder Asset Management's ACAD Position: Q2 2026 in Review

Meeder Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 984 shares — an estimated $21.9K sold.

Meeder Asset Management first reported a position in ACAD in Q4 2017 and held it in 18 quarters. The position peaked at $448K in Q1 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Meeder Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 984 Acadia Pharmaceuticals shares in Q2 2026, an estimated $21.9K.
  • Meeder Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 18 quarters.
  • Meeder Asset Management's Acadia Pharmaceuticals position peaked at $448K in Q1 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.